Industry Updates for the Psychedelics World | Page 14 of 35

Psychedelics News

Industry

11 Jan 2023

Algernon Pharmaceuticals Announces Plans for 180 Patient Phase 2b Study

Algernon continues to move its programs forward, as it announces plans for a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3...

By Microdose NewsDesk

Industry

11 Jan 2023

Key Takeaways from MindMed’s 2023 Corporate Update

On January 9th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO:MMED) released its 2023 corporate update....

By James Hallifax

Industry

10 Jan 2023

Enthea Offers Access to Psychedelic Therapy With Health Insurance Plans

Enthea is a licensed, third-party administrator of health insurance benefits working to provide safe and affordable access to psychedelic-assisted psychotherapies....

By Microdose

Industry

10 Jan 2023

A Deeper Look at atai Life Sciences’ Company Update

atai Life Science has released its most recent corporate update....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Jan 2023

Secretive GH Research Provides Business Updates and Upcoming Milestones

Secretive psychedelic drug developments firm GH Research has released its most recent business update and upcoming milestones....

By Microdose NewsDesk

Breaking News, Industry

6 Jan 2023

Atai Announces Disappointing Results in PCN-101 Phase 2a Trial

atai Life Sciences Phase 2a study of PCN-101 (R-ketamine) for treatment-resistant depression was the most anticipated milestone of the second part of 2022....

By Microdose NewsDesk

Industry

5 Jan 2023

MAPS’ Positive Results Confirmed in Second Phase 3 Trial

MAPS has announced that the second part of its Phase 3 trial of MDMA-assisted therapy for PTSD has confirmed prior positive trial results....

By Microdose NewsDesk

Industry

4 Jan 2023

Top 3 Psychedelic Storylines to Watch in 2023

2022 was a milestone year for the psychedelic industry, and 2023 is shaping up to be an even more paradigm-shifting....

By James Hallifax

Finance, Industry

3 Jan 2023

Algernon Forms Private Subsidiary to Advance DMT Stroke Program

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result